文献速递皮肤肿瘤

高危黑色素瘤人群三维全身摄影的成本效果分析

Cost-Effectiveness Analysis of 3D Total-Body Photography for People at High Risk of Melanoma.
PubMed 文献 · JAMA Dermatol · 2025-01-01

该随机临床试验预设成本效果分析纳入309例高危黑色素瘤成人,比较3D全身摄影联合序贯数字皮肤镜成像与常规护理。干预组人均费用1708美元,对照组763美元,增量成本945美元,质量调整生命年两组相似,每额外切除一个恶性皮肤肿瘤的增量成本为40美元。

要点

  • 3D全身摄影联合远程皮肤科医生审核较常规护理增加人均成本945美元。
  • 两组质量调整生命年相似,干预组检出恶性皮肤肿瘤数量与常规护理相近。
  • 每额外切除一个恶性皮肤肿瘤的增量成本为40美元。

核心结论

  • 在高危黑色素瘤队列中,2年内3D全身摄影联合序贯数字皮肤镜成像模式较常规护理产生更高成本,且检出的恶性皮肤肿瘤数量相似。
  • 成本效果是实现临床转化的必要但不充分条件,未来需研究人工智能辅助系统整合后的其他获益。

研究设计与样本

  • 基于随机临床试验数据的预设成本效果分析,样本量309例,随访2年,在澳大利亚布里斯班一家研究医院开展,采用卫生系统视角。
  • 纳入18岁及以上、原发性或后续黑色素瘤高风险成人。

主要发现

  • 干预组较对照组黑色素瘤切除更少,角质形成细胞癌和良性病变切除更多,活检标本更多。
  • 24个月内干预组人均费用1708美元(95%CI 1455-1961),对照组763美元(95%CI 655-870),增量成本945美元(95%CI 738-1157)。
  • 人均质量调整生命年干预组1.84(95%CI 1.82-1.86),对照组1.84(95%CI 1.83-1.86)。
  • 每额外切除一个恶性皮肤肿瘤的增量成本为40美元(95%CI 34-48)。

关键数值与推荐

  • 干预组接受常规护理加初级临床医生基线及6、12、18、24个月临床皮肤检查,并由远程皮肤科医生审核3D全身摄影联合序贯数字皮肤镜成像。
  • 对照组继续常规护理并每6个月完成在线调查。

临床怎么用

  • 在高危黑色素瘤人群中,3D全身摄影联合序贯数字皮肤镜成像模式较常规护理增加医疗成本,但未显示质量调整生命年获益。
  • 该模式检出的恶性皮肤肿瘤数量与常规护理相似,临床实施需综合考虑成本效果及其他潜在获益。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Greater use of novel digital technologies could be associated with improved health outcomes and save health care costs by detecting smaller melanomas earlier (needing less treatment) or benign tumors (needing no treatment). OBJECTIVE: To compare costs and health effects of 3-dimensional (3D) total-body photography (TBP) and sequential digital dermoscopy imaging (SDDI) vs usual care for early detection of melanoma. DESIGN, SETTING, AND PARTICIPANTS: This prespecified cost-effectiveness analysis using randomized clinical trial (n = 309) data with 2 years of follow-up was conducted at a research hospital in Brisbane, Australia, and took a health system perspective. It included adults 18 years or older at high risk of developing a primary or subsequent melanoma. INTERVENTION: The intervention group received usual care plus clinical skin examinations by junior clinicians at baseline and 6, 12, 18, and 24 months with 3D TBP-SDDI reviewed by a teledermatologist. The control group continued to receive usual care and completed online surveys every 6 months. MAIN OUTCOMES AND MEASURES: Government health care costs, patient out-of-pocket costs, numbers of benign and malignant skin tumor excisions, and quality-adjusted life-years. Skin biopsy, excisions, pathology, and their costs were collected using administrative claims data. Quality of life was collected using the EuroQol-5D-5L. RESULTS: The trial included 314 participants (mean [SD] age, 51.6 [12.8] years; 194 female individuals [62%]) who completed all of the study procedures (158 in the intervention and 156 in the control groups). Compared with controls, intervention group participants had fewer melanoma excisions, more keratinocyte carcinomas and benign excisions, and more biopsy specimens. Over 24 months, mean per-person costs (analyzed in Australian dollars and converted to US$) for the intervention group were $1708 (95% CI, $1455-$1961) vs $763 (95% CI, $655-$870) for controls, an incremental cost of $945 (95% CI, $738-$1157) to provide the intervention. Total quality-adjusted life-years per person were similar for the intervention (1.84; 95% CI, 1.82-1.86) and control groups (1.84; 95% CI, 1.83-1.86). The incremental cost per additional malignant skin tumor excised was $40 (95% CI, $34-$48). CONCLUSIONS AND RELEVANCE: Over 2 years of the trial, the 3D TBP-SDDI model by junior clinicians and teledermatologist review generated higher costs and detected similar numbers of malignant tumors than usual care in a high-risk melanoma cohort. Cost-effectiveness is a necessary but not sufficient consideration for implementation. Other benefits of 3D TBP-SDDI may arise once artificial intelligence clinician support systems are integrated, and more research is needed to understand factors associated with costs and whether there are other benefits of 3D TBP-SDDI.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lindsay D, Soyer HP, Janda M, et al. Cost-Effectiveness Analysis of 3D Total-Body Photography for People at High Risk of Melanoma. JAMA Dermatol. 2025. PMID: 40136266. doi:10.1001/jamadermatol.2025.0219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。